| Entry |
|
|---|
| Name |
Pegnartograstim (USAN/INN) |
|---|
| Sequence |
MAPTYRASSL PQSFLLKSLE QVRKIQGDGA ALQEKLCATY KLCHPEELVL LGHSLGIPWA
PLSSCPSQAL QLAGCLSQLH SGLFLYQGLL QALEGISPEL GPTLDTLQLD VADFATTIWQ
QMEELGMAPA LQPTQGAMPA FASAFQRRAG GVLVASHLQS FLEVSYRVLR HLAQP
(Disulfide bridge: 37-43, 65-75) |
|---|
| Type |
Peptide |
|---|
| Class |
Immunological agent
DG01753 Colony stimulating factor
DG01781 Granulocyte colony stimulating factor (G-CSF)
|
|---|
| Efficacy |
Antineoplastic, Immunomodulator |
|---|
| Comment |
see Nartograstim [DR: D03245]
Parenteral adjuvant to anticancer chemotherapy
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04060 | Cytokine-cytokine receptor interaction |
|
|---|
| Brite |
Drug groups [BR:br08330]
Immunological agent
DG01753 Colony stimulating factor
DG01781 Granulocyte colony stimulating factor (G-CSF)
D05389 Pegnartograstim
Target-based classification of drugs [BR:br08310]
Signaling molecules and receptors
Cytokine receptors
CSF and other factor receptors
CSF3R (GCSFR, CD114)
D05389 Pegnartograstim (USAN/INN)
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
